FI955312A - Staurosporiinijohdannaisen intravenoosit liuokset - Google Patents

Staurosporiinijohdannaisen intravenoosit liuokset Download PDF

Info

Publication number
FI955312A
FI955312A FI955312A FI955312A FI955312A FI 955312 A FI955312 A FI 955312A FI 955312 A FI955312 A FI 955312A FI 955312 A FI955312 A FI 955312A FI 955312 A FI955312 A FI 955312A
Authority
FI
Finland
Prior art keywords
sturosporine
derivative
intravenous solutions
intravenous
solutions
Prior art date
Application number
FI955312A
Other languages
English (en)
Swedish (sv)
Other versions
FI955312A0 (fi
Inventor
Hans Georg Weder
Ute Isele
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI955312A0 publication Critical patent/FI955312A0/fi
Publication of FI955312A publication Critical patent/FI955312A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI955312A 1994-11-09 1995-11-06 Staurosporiinijohdannaisen intravenoosit liuokset FI955312A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH337594 1994-11-09
CH59595 1995-03-02

Publications (2)

Publication Number Publication Date
FI955312A0 FI955312A0 (fi) 1995-11-06
FI955312A true FI955312A (fi) 1996-05-10

Family

ID=25685065

Family Applications (2)

Application Number Title Priority Date Filing Date
FI955312A FI955312A (fi) 1994-11-09 1995-11-06 Staurosporiinijohdannaisen intravenoosit liuokset
FI955311A FI955311A (fi) 1994-11-09 1995-11-06 Farmaseuttinen koostumuspohja

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI955311A FI955311A (fi) 1994-11-09 1995-11-06 Farmaseuttinen koostumuspohja

Country Status (11)

Country Link
US (1) US5658898A (fi)
EP (2) EP0711557A1 (fi)
JP (2) JPH08208522A (fi)
KR (2) KR960016908A (fi)
AU (2) AU3661695A (fi)
CA (2) CA2162342A1 (fi)
FI (2) FI955312A (fi)
HU (2) HUT74423A (fi)
IL (2) IL115913A0 (fi)
NO (2) NO954485L (fi)
NZ (2) NZ280419A (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
WO1997021428A1 (de) * 1995-12-12 1997-06-19 Vesifact Ag Cortisolspray zur topischen verabreichung
DE19622224A1 (de) 1996-02-16 1997-08-21 Max Planck Gesellschaft Phosphatidyloligoglycerine
DE69738416T2 (de) * 1996-06-18 2008-12-11 Kyowa Hakko Kogyo Co., Ltd. Liposomale zubereitungen von indolocarbazol-derivaten
US6537561B1 (en) * 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
WO1999025319A1 (en) * 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
US7381423B2 (en) 1998-05-11 2008-06-03 Ciba Specialty Chemicals Corp. Use of nanodispersions in cosmetic end formulations
TW592713B (en) * 1998-05-11 2004-06-21 Ciba Sc Holding Ag Use of nanodispersions in cosmetic end formulations
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
DE69929128T2 (de) * 1998-08-31 2006-06-29 Nipro Corp. Nährstoffinfusionspräparat
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
CN1582150B (zh) * 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
KR100422763B1 (ko) * 2002-01-17 2004-03-12 주식회사 태평양 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물
KR100490365B1 (ko) * 2002-04-25 2005-05-17 한불화장품주식회사 화장료용 나노 베지클을 함유하는 화장료 조성물
EP1531793A1 (en) * 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
EP1613766A1 (de) * 2003-03-03 2006-01-11 Florian Physiologisches Institut I Lang Sgk1 als diagnostisches und therapeutisches target
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
AU2004262927B2 (en) 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
JP5135852B2 (ja) * 2007-03-30 2013-02-06 日油株式会社 可溶化用組成物
KR100849537B1 (ko) * 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2013086526A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Liposomal drug encapsulation
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348214A (ja) * 1986-08-18 1988-02-29 Morishita Seiyaku Kk １−〔２−（２，４−ジクロロフエニル）−３−メチル−１−ペンテニル〕−１ｈ−イミダゾ−ルを含有する水中油型脂肪乳剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
CH677886A5 (fi) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
AU675930B2 (en) * 1992-02-18 1997-02-27 Pharmos Corp. Dry compositions for preparing submicron emulsions
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions

Also Published As

Publication number Publication date
AU3661795A (en) 1996-05-23
KR960016890A (ko) 1996-06-17
FI955311A0 (fi) 1995-11-06
JPH08208486A (ja) 1996-08-13
HUT78026A (hu) 1999-05-28
HU9503198D0 (en) 1996-01-29
HU9503199D0 (en) 1996-01-29
NO954486L (no) 1996-05-10
EP0711557A1 (de) 1996-05-15
KR960016908A (ko) 1996-06-17
FI955312A0 (fi) 1995-11-06
NO954486D0 (no) 1995-11-08
NZ280419A (en) 1997-04-24
IL115912A0 (en) 1996-01-31
AU3661695A (en) 1996-05-23
US5658898A (en) 1997-08-19
CA2162341A1 (en) 1996-05-10
EP0711556A1 (de) 1996-05-15
IL115913A0 (en) 1996-01-31
NO954485D0 (no) 1995-11-08
JPH08208522A (ja) 1996-08-13
CA2162342A1 (en) 1996-05-10
NO954485L (no) 1996-05-10
HUT74423A (en) 1996-12-30
NZ280420A (en) 1997-03-24
FI955311A (fi) 1996-05-10

Similar Documents

Publication Publication Date Title
FI955312A (fi) Staurosporiinijohdannaisen intravenoosit liuokset
DK1340475T3 (da) Et katetersystem
BR9509760A (pt) Composto
DE69424027D1 (de) Katheter
NO944047D0 (no) Strömningsledet kateter
NO952854D0 (no) 1-arylpyrimidin-derivater
DE69527561D1 (de) Munddusche
DE69626168D1 (de) Infusionskatheter
DE59508427D1 (de) 3-aryl-4-hydroxy-delta 3 -dihydrothiophenon-derivate
DE69423046D1 (de) Schnellzurückziehbarer katheter
FI945085A0 (fi) Yhdistelmä-neu-reseptoristimulaatiotekijä
DE69329894D1 (de) Arylamidderivate
DE69505537D1 (de) Verallgemeinerter konfigurierer
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
BR9508339A (pt) Medicamento
BR9406092A (pt) Cateter
IS4321A (is) Nýjar díalkoxý-pýridínýl-bensimidasólafleiður
NO965233D0 (no) Deacetoksytaksol-derivat
DE69527786D1 (de) Diaminomethyliden-derivate
NO970144L (no) Trifluormetylkinolinkarboksylsyre-derivat
DE59509209D1 (de) Diphenyloxazolin-derivate
MD196B1 (ro) Izonicotinoilhidrazona a aldehidei 5-nitro-2-furanice
DE69510792D1 (de) Naphtochinonderivate
FI972204A (fi) Suonensisäisiä lubelutsoliliuoksia
NO932638D0 (no) 21-klor-pregnanderivat

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG